CHANGES IN THE LEVEL OF C-REACTIVE PROTEIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WHILE TAKING COLCHICINE
Keywords:
Colchicine, C-reactive protein, percutaneous coronary admixture (PCI), atherosclerosis, CADAbstract
Purpose: To study the effect of colchicine on the level of C-reactive protein in patients undergoing percutaneous coronary intervention (PCI).
Materials and methods: We conducted an analysis with coronary heart disease, who underwent myocardial infarction, underwent PCI from August 1 to November 1, 2022 according to the Samarkand regional regional branch of the Republican Specialized Scientific and Practical Medical Center for Cardiology. A total of 52 patients were analyzed, who underwent interventional intervention (PCI), stenting of the coronary arteries with radial access.
Conclusion: The use of colchicine at a dose of 0.5 mg per day for 3 months after PCI significantly reduced the level of C-reactive protein, and in the group without colchicine, CRP remained practically at the same positions.
References
ANZCTR. LoDoCo2 study: low-dose colchicine for secondary prevention of cardiovascular disease;2014 ACTRN12614000093684
Agababyan, I., Yarasheva, Z., Nasretdinova, M. The Importance of Echocardiography in the Detection of Early Chronic Heart Failure in Elderly Patients Kardiologija v Belarusithis link is disabled, 2022, 14(3), pp. 313–318
Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG, Poiani G et al. Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. Journal of Clinical Medicine. 2020;9(9):2961. DOI: 10.3390/jcm9092961
Kobilova N. A., Jabbarova N. M Effect of cardioprotectors on quality of life of patients with ischemic heart disease complicated with chronic heart failure //журнал биомедицины и практики. – 2022. – Т. 7. – №. 1.
Kobilova N. A.триметазидин в комбинированной терапии ишемической болезни сердца, перенесших инфаркт миокарда //Journal of cardiorespiratory research. – 2021. – Т. 1. – №. 4. – С. 31-33.
Libby P., Loscalzo J., Ridker P.M. et al. Inflammation, immunity, and infections in atherothrombosis: topic of the week for JACC review. J. Am Call Cardiol 2018; 72:2071-81.
Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018; 269:262– 71. DOI: 10.1016/j. atherosclerosis.2017.12.027.
Montealegre-Gómez G, Garavito E, Gómez-López A, Rojas-Villarraga A, Parra-Medina R. Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients. Reumatología Clínica. 2020; [Epub ahead of print]. DOI: 10.1016/j.reuma.2020.05.001
Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high- ensitivity C- reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99:805e807.
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. Am Coll Cardiol. 2013; 61: 404e410.
Ridker P.M., Everett B.M., Pradhan A. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019; 380:752-62.
Ridker P.M., Everett B.M., Touraine T. et al. Anti-inflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377:1119-31.
Rizaev E. A., Agababyan I. R., Arzikulova M. Sh. K. Autoimmune inflammation as a causal relationship of periodontitis and atherosclerosis // Problems of Science and Education. – 2022. – no. 6 (162). - S. 50-64. (in Uzbekistan)
Tardif JK, Koose S, Waters DD et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019; 381:2497-505.
Yang M, Lv H, Liu Q, Zhang L, Zhang R, Huang X et al. Colchicine Alleviates Cholesterol Crystal-Induced Endothelial Cell Pyroptosis through Activating AMPK/SIRT1 Pathway. Oxidative Medicine and Cellular Longevity. 2020; 2020:9173530. DOI: 10.1155/2020/9173530
J.A. Rizaev, I.R.Agababyan, Y.A.Ismoilova ACTIVITIES OF CLINICS SPECIALIZING IN THE TREATMENT OF PATIENTS WITH CHRONIC HEART DISEASE IN THE WORLD (REFERENCES). Journal of Biomedicine and Practice. 2021, vol. 6, issue 6, pp. 184-191
